Company ProfilePremium

Clinomics Inc.

Company Profile Analysis

Ticker: 352770.KQ주식회사 셀레스트라

ESOMAR 23 Corporate BadgeISO Certifications Badge
Clinomics Inc. - Company showcase

Year Founded & Workforce

2011

78 Employees

Clinomics Inc. logo

Clinomics Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Clinomics Inc. Overview

Celestra Inc., known until 2025 as Clinomics, was founded in 2011 as a liquid-biopsy and cancer-genomics company. In 2018 it merged with Zeromics, the genome-analysis company of UNIST professor Park Jong-hwa. It was the first UNIST faculty start-up to list on KOSDAQ, through the growth-potential special-listing track in December 2020. Its stated platform combined multi-omics genome analysis, an in-house device for isolating circulating tumour cells and cell-free DNA, and consumer and clinical genetic tests. COVID-19 testing, mainly through its US subsidiary, drove a one-off peak in FY2021 of KRW 55.4bn revenue and KRW 22.9bn operating profit. After demand collapsed, the company recorded large losses. Control passed to a new investor group in 2024, and the company moved into a hotel, a mushroom smart farm and health supplements. By 2025–2026 it had received two audit disclaimers, entered and then exited court rehabilitation, and was facing delisting. Its core diagnostics business has effectively stopped operating.


Company's own characterisation

The company's latest annual report (FY2025 business report) could not be retrieved directly. The most recent company-sourced business descriptions, as summarised by data vendors, are:

Core description (GuruFocus / Morningstar profiles): a biotechnology company offering genome-based early diagnosis of cancer and other diseases, which aims to address ageing and disease through liquid biopsy and multi-omics technology.

Business lines (EMIS profile, based on 2023 data): two main businesses.

  • A multi-omics service business that predicts physical traits and disease risk from genome tests and offers multi-omics-based early detection of major diseases such as cancer.

  • A liquid-biopsy cancer diagnosis and screening business that sells devices for isolating blood cells and DNA, along with diagnostic and monitoring kits for cancer mutations. It is also developing blood-based early cancer detection products.

Main products listed in IR disclosures (IRGO): Geno Series, CD-PRIME, Cancer Prime.

2025-era description (TheVC): NGS-based contract research services under B2B and B2C models, with revenue diversification through health functional foods and a hotel business.

Independent characterisation

From IPO to 2023, Clinomics was a small Korean clinical-genomics and liquid-biopsy services company. Its business model mixed three things:

  1. Fee-for-service testing: consumer DTC genetic tests, clinical cancer panels and research sequencing.

  2. Device and kit sales: liquid-biopsy sample-preparation devices and cancer-mutation kits.

  3. Pandemic testing: COVID-19 diagnostic kits and lab testing, mainly through Clinomics USA in 2020–2022.

The COVID business masked the fact that the core genomics products never reached commercial scale (Bizwatch, Nov 2025). After the change of control in 2024, the company became a loosely connected holding of unrelated assets: a Seoul hotel, a 40% stake in a mushroom smart farm (Gageum Nongsan), and a health-supplement subsidiary (CoNF). The financial press reported that these acquisitions were made partly to stay above the KOSDAQ revenue threshold that triggers "administrative issue" designation (Financial News, Jul 2025; The Tracker, Sep 2025).

By 2026, operating activity was minimal. Standalone Q1 2026 revenue was about KRW 24 million. In the H1 2026 report, the company confirmed that Q2 revenue was below KRW 300 million and H1 revenue below KRW 700 million, and that its equity was fully impaired.

Revenue model mix

Revenue typeDescriptionApprox. weight
Testing services (product-like service fees)Genome, DTC and cancer tests; COVID-19 testing (historic)Dominant in FY2020–FY2022. Exact split not publicly disclosed.
Product salesLiquid-biopsy devices, diagnostic kits, COVID kits, health functional foods—
Research servicesNGS-based contract research—
HospitalityNew Oriental Hotel (acquired 2024)Not publicly disclosed. The hotel was reported as not operating at acquisition.
Subscription / licensingGenpic app (an affiliate's app, not consolidated revenue); distribution of Singlera tests—

Value-chain position, customers and end-markets

Value chain: a mid-stream analysis-service provider. It sourced sequencing platforms from third parties and licensed some tests (Singlera's), while running its own lab analysis, bioinformatics and reporting. Its in-house sample-preparation device for CTC and ctDNA isolation was the main upstream differentiator.

Customers: hospitals and clinics (cancer panels), consumers (DTC tests under Korea's limited DTC regime), research institutions (sequencing services), government (it carried out national R&D projects, including 2023 work on infectious diseases and epidemiological and mathematical modelling, per TheVC), and in 2020–2022 COVID-testing clients in the US.

End-markets: precision oncology and liquid biopsy, consumer genomics and wellness, infectious-disease diagnostics, and from 2024 hospitality and agri-food.

Strategy

Stated strategic themes (company statements, paraphrased)

At IPO (2019–2021): become a bio-big-data-based disease prediction and diagnosis company. Pursue multi-omics early cancer detection through multi-centre trials in colorectal, lung and gastric cancer. Build genome big-data infrastructure in Ulsan, Gwanggyo and Osong. Recruit global talent from the UK and US.

2022 mission framing (IR deck): a three-step path from genome company to disease-diagnosis company to disease-treatment company, under the goal of people living longer without illness.

2022 healthcare roadmap: offer personalised health information from genetic, health and life-log data, and prescribe exercise, diet, teas and supplements. Expand into wellness and beauty devices (CEO Jung Jong-tae, Oct 2022).

2023 early cancer detection: take an early lead in the cancer-screening market, which the company sized at tens of trillions of won, through exclusive supply of Singlera's tests in the US, Europe and Korea (CEO Kim Byung-chul, May 2023).

  • 2024 "Genocare" project (Clinic, Application, Report, Engine): use the Geno Engine for large-scale genome data and AI to generate reports, personalised supplements (via Gageum Nongsan and CoNF) and clinic services. Build a big-data platform combining EMR and personal health data with partners in universities, hospitals, pharma, insurance and food. Develop ADC, glyco-engineered drugs and anti-ageing ("reverse aging") products. A planning and marketing new-business division was created.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailOutcome
Fifth-series CB financingMar 2025Working capital for existing and new businessesRedeemed early, Apr 2025
15:1 capital reductionApr 2025Offset accumulated deficitCompleted 17 Apr 2025
Re-audit planJul 2025IB sources said a re-audit was planned to obtain a clean opinion and resume tradingNot achieved; FY2025 also disclaimed
Stalking-horse sale of the companyJul 2025Samil PwC appointed sale adviserNo buyer disclosed
Court rehabilitationSep 2025 – Aug 2026Filed 8 Sep 2025; commenced 30 Sep 2025; about 10 public notices through Jun 2026Terminated 20 Aug 2026; no plan filed
Hotel resale2,025Divestment of New Oriental HotelOutcome not disclosed
Investor search / re-filing for rehabilitationAug 2026Company said it would consider re-filing once a new investor is securedPending
Injunction against delistingJun 2026 –Court challenge to the KRX decisionPending at cut-off

Medium-term targets and guidance

TargetSetActual
Revenue of at least KRW 20bn in 2024Jul 2024 (Genocare)KRW 8.5bn (FY2024)
Revenue of at least KRW 50bn and profitability from 2025Jul 2024 (Genocare)KRW 2.0bn revenue, KRW 7.8bn operating loss (FY2025)
Equity ratio from 44.89% to 67.59% via 2023 rights offeringMay 2023Rights offering downsized; ratio outcome not disclosed

No current guidance has been published. ESG and sustainability commitments are not publicly disclosed.

Products & Services

The list below covers every product that could be identified. Specifications and pricing are mostly not publicly disclosed.

Genome / multi-omics services

ProductDescriptionTarget customerLaunch / statusPricing
Geno Series (incl. Geno-P)DTC genetic tests within Korea's permitted DTC test items. Geno-P was one of about 10 genome tests offered at IPO.ConsumersPre-2021—
Genome-based personalised healthcare testsTrait and disease-risk prediction from genome analysisConsumers, clinicsPre-2021—
Multi-omics early disease detectionEarly detection of major diseases including cancerHospitals, health-screening centresUnder development; commercialisation targeted for 2023—
Stress/depression early diagnosis serviceDevelopment project targeting commercialisation in 2023ClinicsStatus not disclosed—
NGS research servicesSequencing-based contract researchUniversities, institutes, governmentOngoing (TheVC)—
Geno Engine / Geno ReportLarge-scale genome data production and AI/multi-omics reporting (Genocare framework)B2B partners, clinicsAnnounced Jul 2024—

Liquid biopsy and cancer diagnostics

ProductDescriptionTarget customerLaunch / statusPricing
CTC/ctDNA isolation platformPlatform that separates circulating tumour cells and cell-free tumour DNA from blood. Founder Kim cited owning both capabilities as the company's key differentiator.Oncology labs, hospitalsPre-IPO—
CD-PRIMEListed as a main product (IRGO). Detailed specifications not publicly disclosed.Oncology——
Cancer PrimeListed as a main product (IRGO); cancer companion-diagnostic / panel offeringOncology——
Cancer mutation diagnostic and monitoring kitsKits for patient cancer-mutation detection and monitoringHospitalsPre-2023—
Liquid-biopsy early cancer detection platformBlood-based early detection; multi-site trials planned for colorectal, lung and gastric cancerScreening marketDevelopment; commercialisation targeted for 2023—
ColonES (Singlera)Colorectal cancer early detectionUS market via Clinomics USALaunch planned H2 2023—
PDACatch (Singlera)Pancreatic cancer early detectionUS marketLaunch planned H2 2023—
Panseer MRD (Singlera)Multi-cancer / minimal residual disease testingUS marketLaunch planned H2 2023—
ColonAiQ (Singlera)Colorectal cancer screeningEurope via Clinomics EULaunch planned 2023—
HepaAiQ (Singlera)Liver cancer screeningEurope via Clinomics EULaunch planned 2023—

Actual commercial revenue from the Singlera-licensed tests was not publicly disclosed. Consolidated revenue fell after 2023, which suggests sales were immaterial.

Infectious disease (historic)

ProductDescriptionStatus
COVID-19 diagnostic kits and testing servicesTesting infrastructure in Korea, the US and Europe; US lab testing drove FY2021 revenueEnded after the pandemic

Therapeutics R&D

ProgramDescriptionStatus
AI personalised cancer vaccine (Zeromics)Neoepitope prediction via AI "bio genome engine"; humanised-mouse preclinical work with HumicMOU Aug 2023; no later progress disclosed
Glyco-engineering drugs, ADC technologiesListed as partnership targets under GenocareConcept stage (Jul 2024)

Wellness, health foods and non-core

Product / assetDescriptionStatus
"Epi's Today" (에피의오늘)Supplement brand of subsidiary Episday (diet tea, nutritional supplements)Launched 2022
CoNF health functional foodsPersonalised and anti-ageing supplementsAcquired 2023
Genpic app (affiliate The Contest)Post-test personalised health content by subscriptionLaunched 1 Oct 2022
New Oriental HotelSeoul hotel; reported as not operating at acquisitionBeing resold (Nov 2025)
Gageum Nongsan mushroom smart farm (40%)Automated mushroom cultivationHeld (status not disclosed)

Financial Narrative

Source: Butler.works company page (OpenDART-based consolidated annual data, FY2021–FY2025). FY2021–FY2022 figures are cross-checked with Bizwatch (Nov 2025) and FY2022/FY2024 with The Tracker (Sep 2025). FY2024 and FY2025 statements carry disclaimers of opinion. Blank cells mean not publicly disclosed in accessible sources.

Income statement

FY2020 reference: revenue KRW 9.8bn, operating loss KRW 12.3bn (Daishin IPO report). The FY2021 growth rate is calculated against this base. The company has never paid a dividend (GuruFocus).

Margins (%)

Margins are calculated from the rounded figures in 6.1.

Revenue CAGR: FY2021–FY2025 about -56.4% a year (KRW 55.4bn to KRW 2.0bn). FY2020–FY2025 about -27.2% a year.

Cash flow

Line-item cash flows are not publicly disclosed in accessible sources. Bizwatch (Nov 2025) reports that the company burned several billion to tens of billions of won each year across operating and investing activities, funded by CBs, rights offerings and borrowings. It also reports that the KRW 30bn CB raised in 2021 had to be repaid with proceeds from the 2023 shareholder rights offering.

Financing events (chronological):

TheVC records a total of six CB issues over the company's history.

Ratios

Current ratio source: TheVC (financial detail summary, FY2023–FY2025).

Commentary on trends, inflections and drivers

FY2021 (peak): Revenue of KRW 55.4bn and operating profit of KRW 22.9bn came from pandemic COVID testing, which exploded through the US subsidiary (Bizwatch). The 41% operating margin reflects pandemic testing economics, not the core genomics business. This was the single point at which the company had resources. It used them to buy a building in Irvine and a lab in San Diego and to raise KRW 30bn in CBs, rather than to build lasting revenue in its core business.

FY2022 (first inflection): As COVID testing faded, revenue fell 58% to KRW 23.1bn and the company swung to an operating loss of KRW 10.8bn. R&D, clinical, equipment and personnel costs stayed fixed while no new cash generator emerged (Bizwatch). The company also committed KRW 8.2bn to Nuribio.

FY2023 (collapse in profitability): Revenue halved again to KRW 11.4bn and the operating loss tripled to KRW 34.6bn. The net loss of KRW 42.4bn likely includes impairments and valuation losses, though the components were not disclosed. Pre-tax loss reached 108.8% of equity, more than twice the 50% KOSDAQ threshold. The special-listing exemption from that test lasts three years, so it expired around this time (Dealsite, Jul 2024). The auditor flagged going-concern uncertainty.

FY2024 (pivot to non-core assets): Under new control, the company bought a hotel (KRW 18.5bn) and a farm stake to support revenue. Revenue still fell to KRW 8.5bn against a KRW 20bn target, and the net loss widened to KRW 47.1bn. The audit ended in a disclaimer.

FY2025 (wind-down): Revenue of KRW 2.0bn was down about 76%. The operating loss narrowed to KRW 7.8bn, which reflects a smaller cost base (employees fell toward single digits by mid-2026), not recovery. The current ratio fell to 27.3%, meaning current assets covered about a quarter of current liabilities. A second disclaimer followed.

H1 2026: Q1 standalone revenue was about KRW 24 million. Revenue thresholds under the KOSDAQ "suspended main business" test were breached in Q1, Q2 and H1, and equity was fully impaired at 30 June 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (as described)ContentsStatus at cut-off

Multi-omics / genome-based healthcare services

DTC and clinical genetic tests (Geno Series, Geno-P), multi-omics early detection, NGS research services, big-data analysis

Effectively dormant. H1 2026 revenue below KRW 0.7bn.

Liquid-biopsy cancer diagnosis and screening

CTC/ctDNA isolation devices, cancer mutation diagnostic and monitoring kits (CD-PRIME, Cancer Prime), Singlera-licensed screening tests

Not publicly disclosed; no evidence of current sales

COVID-19 diagnostics (historic)

Kits and lab testing, mainly via Clinomics USA

Ended after the pandemic

Health functional foods

CoNF subsidiary, Episday ("Epi's Today" brand), personalised supplements under Genocare

—

Hospitality

New Oriental Hotel, Seoul

Being resold (Bizwatch, Nov 2025); outcome not disclosed

Agri-food (equity-accounted)

40% of Gageum Nongsan (mushroom smart farm)

—

“—” = not publicly disclosed.

Revenue by Segment

Segment (KRW Bn)FY2023FY2024FY2025

Total consolidated revenue (KRW Bn)

11.48.52.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityRelationshipBusinessSource

Clinomics USA Inc.

Subsidiary

US operations: COVID testing (2020–22), distribution of Singlera's ColonES, PDACatch and Panseer MRD; Irvine, CA building

IR 2021; Medigate (May 2023); Bizwatch (Nov 2025)

Clinomics EU

Subsidiary/branch

European launch of ColonAiQ and HepaAiQ screening (planned 2023)

Medigate (May 2023)

Zeromics (제로믹스)

Subsidiary (2023 reference)

AI-based anti-cancer and anti-ageing drug development; cancer-vaccine system

Medigate (Aug 2023)

Episday (에피스데이)

Subsidiary (est. early 2022)

Health functional foods ("Epi's Today")

Medigate (Oct 2022)

CoNF (코엔에프)

Subsidiary (acquired 2023)

Health functional foods

Medigate (May 2023); Asiae (Jul 2024)

Gageum Nongsan (가금농산)

40% equity stake (2024)

Mushroom smart farm / automated cultivation

Financial News (Jul 2025)

Nuribio (누리바이오)

28.40% equity stake (Nov 2022)

Cancer early-diagnosis related

Dealsite (Nov 2022)

The Contest (더콘테스트)

Affiliate

Genpic gene-based health app

Medigate (Oct 2022)

New Oriental Hotel

Owned asset (acquired May 2024)

Hotel, Jung-gu, Seoul

Financial News (Jul 2025)

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

55.423.111.48.52.0

Revenue growth YoY (%)

465.3-58.3-50.6-25.4-76.5

Operating income (KRW Bn)

22.9-10.8-34.6-28.7-7.8

Net income (KRW Bn)

15.9-10.2-42.4-47.1-11.8

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating margin (%)

41.3-46.8-303.5-337.6-390.0

Net margin (%)

28.7-44.2-371.9-554.1-590.0

Key Financials and Margin Analysis (%)

MetricFY2021FY2023FY2024FY2025

Accumulated deficit (KRW Bn)

26.3———

Current ratio (%)

—135.437.727.3

Datapoint Details

DatapointValueDateSource

Accumulated deficit

KRW 60.5bn

Q3 2024

Dealsite (Mar 2025)

Pre-tax loss / equity

108.8%

FY2023

Dealsite (Jul 2024)

Real-estate value (Ulju plant site, Osong lab)

about KRW 9.5bn (due-diligence value)

Jul 2025

Financial News (Jul 2025)

Cash

about KRW 0.63bn

Q3 2025

Craft.co (aggregator)

Equity status

Fully impaired (자본전액잠식)

30 Jun 2026

KRX notice via Topstar News (Aug 2026)

Debt / equity (aggregator snapshot)

0.43

Date not stated

GuruFocus

Cash / debt (aggregator snapshot)

0.54

Date not stated

GuruFocus

Altman Z-score (aggregator)

-1.8

Date not stated

GuruFocus

Piotroski F-score (aggregator)

3/9

Date not stated

GuruFocus

IPO offer price

13,900

Dec 2020

NewsTomato

Price

15,200

29 Jun 2021

Daishin

Price

593

29 Oct 2024 (market cap KRW 22.8bn)

Craft.co

Last traded price (post-reduction basis)

5,250

Halted since Apr 2025

Simply Wall St; Investing.com

52-week high / low (as displayed)

25,410 / 4,245

Aggregator display; reference period unclear

Simply Wall St

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW Bn)

00000

Instrument by Date

DateInstrumentSizeUse / noteSource

Apr 2019

Pre-IPO equity

KRW 22.5bn

Cancer early-detection R&D, clinical trials

DailyPharm

Dec 2020

IPO

—

Growth-potential listing

NewsTomato

2021

Convertible bonds

KRW 30bn

Growth investment; later repaid via 2023 rights offering

Bizwatch

May–Aug 2023

Rights offering + 0.5 bonus issue

Announced KRW 44.6bn; final amount reduced after the price fell about 40%

CB repayment; equity ratio targeted to rise from 44.89% to 67.59%

Medigate; NewsTomato

Apr 2024

Third-party allotment to Geno Investment Association No. 1

KRW 7.6bn

Change of control (12.99%)

Daum/news

2024

CBs (incl. third series KRW 12bn secured on hotel)

KRW 25bn total CBs in that round

Hotel purchase, loan repayment. Of KRW 32.6bn raised, about KRW 6.8bn cash remained.

Daum/news (2024)

18 Mar 2025

Fifth-series CB

About KRW 5–5.5bn

Working capital; redeemed early on 7 Apr 2025

Dealsite; Chosun Biz

17 Apr 2025

Capital reduction 15:1 (93.33%)

—

Offset accumulated deficit

IRGO; Bloter

Margin Analysis (%) (FY2023–FY2025)

RatioFY2023FY2024FY2025

Current ratio (%)

135.437.727.3

Revenue by Region

Region (KRW Bn)FY2023FY2024FY2025

Total revenue (KRW Bn)

11.48.52.0

Capital Markets

Metric1-year3-yearSince IPO

Share price change (%)

-76.5-92.8-97.2

Valuation Multiples

MultipleCelestraMacrogenNote

Market cap (KRW Bn)

13.6132.0

Butler.works (Macrogen at the time of the aggregator snapshot)

P/E (x)

n/m (losses)

12.83

Butler.works

P/B (x)

n/m (equity fully impaired)

0.85

Butler.works

P/S (x)

About 6.8 on FY2025 revenue (13.6 / 2.0). Simply Wall St earlier cited 3.5x at an unspecified 2025 date.

—

Calculated; Simply Wall St

Capital Markets — Analyst consensus / target price

ItemStatus

Analyst consensus / target price

None. No analyst estimates are available (Simply Wall St). The only broker report found is Daishin's mandatory IPO-manager coverage (2021, not rated).

Dividend history / policy

No dividends paid since listing (GuruFocus)

Buyback authorisations

None disclosed; treasury shares 1.50% (Butler.works)

Credit ratings (Moody's / S&P / Fitch)

None (unrated)

Debt maturity profile

Not publicly disclosed. CBs carried a 3% coupon and 9% yield-to-maturity in at least one 2024 issue (Daum/news). Repayment terms are now subject to insolvency outcomes.

Valuation Snapshot

MetricValue

Shares outstanding pre-reduction (Q1 2024)

38,143,171

Capital reduction ratio (Apr 2025)

15 to 1 (93.33%)

Shares outstanding (Jun 2026)

2,592,407

Analyst Conclusions

Management guidance and consensus

The company has published no current guidance. The last quantitative targets (July 2024 Genocare: at least KRW 20bn revenue in 2024 and at least KRW 50bn with profitability from 2025) were missed by wide margins. No sell-side consensus exists. Management's only stated forward intention is to find a new investor and then consider re-filing for rehabilitation (Bloter, Aug 2026).

Bull case

  1. Court relief preserves the listing. If the Seoul Southern District Court grants the injunction (2026카합1390), the delisting decision is suspended, and a listed shell with hard assets could attract a reverse-merger or recapitalisation investor. IB sources said this in July 2025.

  2. Hard-asset backstop. Real estate valued at about KRW 9.5bn (July 2025) plus a hotel bought for KRW 18.5bn is large relative to the stale market cap of about KRW 13.6bn. That gives creditors and any acquirer collateral to work with.

  3. Sector precedent for rescue. EDGC followed the same path (disclaimer, rehabilitation) and was acquired by Erom Holdings for KRW 31.5bn. Distressed Korean genomics assets can find strategic buyers.

Bear case

  1. Multiple independent delisting triggers. Even if the audit-based decision is suspended, other causes remain: quarterly revenue below KRW 300m, H1 revenue below KRW 700m, full capital impairment and rehabilitation termination. Each can sustain delisting on its own.

  2. No going concern. Two audit disclaimers, a 27.3% current ratio, roughly 9 employees, and termination of rehabilitation because no plan could be funded leave equity holders likely to recover nothing in bankruptcy.

  3. Governance and legal overhang. Criminal complaints against the CEO and the questions about related-party CB redemption reduce the chance that any reputable investor commits capital before the investigations conclude.

Key catalysts and monitorables (next 12 months)

  • Ruling on injunction 2026카합1390 (Seoul Southern District Court), and any appeal.

  • Disposition of the November 2025 bankruptcy petition.

  • Any new rehabilitation filing backed by a named investor.

  • Outcome of the hotel resale and of any creditor enforcement against pledged assets.

  • Progress of the complaints lodged with the Suwon District Prosecutors' Office and the FSS.

  • Q3 2026 quarterly report (due mid-November 2026) and its review opinion.

  • KRX action on the substantive-review causes once the injunction is resolved.

  • Details of the 23 September 2026 head-office relocation, as a signal of the remaining operating footprint.

Analyst verdict

Celestra Inc., formerly Clinomics, is no longer an operating genomics company in any meaningful sense. It is a distressed legal entity whose remaining value depends on court decisions, creditor recoveries and possibly a listing shell. The investment case once rested on credible scientific foundations: a UNIST genomics pedigree, a dual CTC/ctDNA isolation platform, 35 patents, and exclusive rights to Singlera's early-detection tests. That case was undone by poor capital allocation.

The FY2021 COVID windfall of KRW 55.4bn revenue and KRW 22.9bn operating profit was not converted into recurring diagnostics revenue. US real estate, equity stakes and CB-funded expansion consumed the cash. After the 2024 change of control, the company bought a dormant Seoul hotel and a mushroom-farm stake to support reported revenue. Revenue still fell to KRW 2.0bn in FY2025, and quarterly standalone revenue reached about KRW 24 million in Q1 2026.

The financial record since FY2024 is effectively unverifiable because of two audit disclaimers. Equity was fully impaired at mid-2026. Rehabilitation failed in August 2026 because no investor could be found. KRX has decided to delist, and only a pending injunction prevents that from taking effect. Even a favourable ruling would leave several other delisting triggers in place, including revenue thresholds and full capital impairment. Criminal complaints against the current CEO add legal risk and further deter capital.

For institutional purposes, the equity should be treated as at high risk of total loss. Value, if any, lies with secured creditors, the real estate (about KRW 9.5bn in mid-2025 estimates) and the hotel, and possibly in a recapitalised shell if the courts and KRX allow it. The case is a clear example of the structural weaknesses Korean commentators have identified in special-listing genomics companies: technology without a proven business model, pandemic revenue mistaken for durable growth, and weak governance during a change of control.

Rating stance (independent): Not rated / avoid. Risk of total loss for equity holders is critical.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / notes

Baek Seo-hyeon (백서현)

CEO (sole CEO after founders left)

Joined management 2023; co-CEO by Q1 2024; sole CEO thereafter

Runs Brand Refactoring, a private digital-marketing company founded in 2022, in which she holds 60%. The market viewed her takeover as effectively hostile (Asiae, Aug 2025). Subject of criminal complaints in Sep 2025 and Aug 2026.

Lee Sang-yoon (이상윤)

Inside director, in charge of R&D

Through at least Mar 2025

Born 1995. Owns 100% of Dominate, the subscriber of the fifth-series CB (Mar 2025).

Jung Jong-tae (정종태)

Formerly CFO/COO (2019), co-CEO (2022–2023); "management head" in the Q1 2024 report

2019 – at least May 2024

Led IPO preparation (IFRS, LIMS, internal systems)

Kim Byung-chul (김병철)

Founder; CEO / co-CEO

2011 – 2024

Ex-POSTECH, Theragen Etex bio-institute. Left in 2024.

Park Jong-hwa (박종화)

Co-CEO (2019); largest shareholder at IPO

Until 2024

UNIST professor; produced the first Korean human genome map. Sold shares in 2023 to fund his rights-offering participation. Left in 2024.

Board & Management Changes

DateChangeContext
2023

Baek Seo-hyeon joins management

Entry of the Geno Investment Association No. 1 group

By Q1 2024

Co-CEOs Kim Byung-chul and Baek Seo-hyeon

Transition period

2024

Founders Kim Byung-chul and Park Jong-hwa leave

After the change of control and non-core acquisitions (Bizwatch)

2024–2025

Baek Seo-hyeon becomes sole CEO

Founders and earlier CEOs were pushed out (Asiae)

Major Shareholders

HolderStakeDateSource

Geno Investment Association No. 1 (Seoul, Gangnam-gu)

12.99%

Apr 2024 (pre-capital-reduction)

KIND ownership report; Daum/news

Park Jong-hwa and 8 related parties

23.90%

Mid-2021 (post-IPO)

Daishin IPO report

Treasury shares

1.50%2026

Butler.works

Dominate (Lee Sang-yoon)

Potential via fifth-series CB conversion rights; CB redeemed Apr 2025

Mar–Apr 2025

Dealsite; Chosun Biz

Competitive Landscape

Key Competitors

CompetitorSegment overlapLatest revenue (verified)Positioning vs. Celestra

Macrogen (KOSDAQ 038290)

NGS services, DTC genomics, clinical genomics

KRW 195.3bn FY2025, +43.8% YoY; operating profit KRW 0.2bn

Market leader with global scale; returned to profit

Eone Diagnomics Genome Center (EDGC, KOSDAQ 245620)

Genome diagnostics, liquid biopsy, NIPT

KRW 30.6bn FY2024; KRW 6.2bn in 9M 2025

Closest analogue: special listing, disclaimer (Apr 2024), rehabilitation (May 2024), sold to Erom Holdings for KRW 31.5bn (deal closing Feb 2026)

Labgenomics (KOSDAQ 084650)

Molecular diagnostics, NGS, COVID testing, US CLIA labs

—

Bought US CLIA labs (QDx, IMD) for about KRW 93bn to replace COVID revenue

Celemics (KOSDAQ)

NGS target-capture kits, sequencing services

KRW 6.7bn FY2024; operating loss KRW 1.9bn

Similar-sized special-listing NGS firm, still listed

Theragen Bio

Genome analysis, DTC

—

Domestic genomics peer

Genomictree

Methylation-based early cancer detection

—

Early-detection rival

Gencurix

Cancer molecular diagnostics

—

Oncology diagnostics rival

Ngenebio

NGS cancer panels

—

Clinical NGS rival

DNA Link

Genome analysis services

—

Domestic genomics peer

GC Genome (private)

Liquid biopsy, NIPT, cancer screening

—

Liquid-biopsy rival

Guardant Health (Nasdaq) / Grail (Nasdaq) / Exact Sciences (Nasdaq)

Global liquid biopsy and multi-cancer early detection

—

Global leaders in Celestra's target category

23andMe (formerly Nasdaq)

DTC genomics

n/a — filed Chapter 11 in Mar 2025

Global evidence of DTC genomics business-model stress

Peer Comparison FY2025

MetricCelestra (FY2025)Macrogen (FY2025)EDGC (FY2024)Celemics (FY2024)

Revenue (KRW Bn)

2.0195.330.66.7

Revenue growth YoY (%)

-76.543.8-65.41.5

Operating income (KRW Bn)

-7.80.2-12.6-1.9

Operating margin (%)

-390.00.1-41.2-28.4

Peer Comparison FY2025 (FY2021–FY2025)

MetricFY2021FY2022FY2023FY2024FY2025

Macrogen revenue (KRW Bn)

129.2138.6132.8135.8195.3

Macrogen operating income (KRW Bn)

11.85.3-0.4-6.50.2

Celestra revenue (KRW Bn)

55.423.111.48.52.0

Celestra operating income (KRW Bn)

22.9-10.8-34.6-28.7-7.8

Company Snapshot

$1.4M

Revenue

78

Employees

2011

Founded

Ulsan, South Korea

Headquarters

SWOT Analysis

Strengths

  • Academic genomics origin: first UNIST faculty start-up to list on KOSDAQ (Dec 2020), with ties to Prof. Park Jong-hwa (Bizwatch; UNIST News).
  • IP portfolio: 35 patents (TheVC, 2026), which were a condition of the 2022 High-Tech Company designation.
  • Liquid-biopsy platform: in-house separation of both CTCs and ctDNA, cited by the founder as the company's differentiator (Biospectator).
  • Hard assets: Ulju plant site and Osong research lab valued at about KRW 9.5bn in July 2025 (Financial News), which is useful in any restructuring.
  • Proven ability to scale testing operations under demand pressure: FY2021 revenue of KRW 55.4bn with a 41.3% operating margin (Butler.works; Bizwatch).
  • Track record with government: 18 national R&D projects and 19 B2G contracts (TheVC).

Weaknesses

  • Revenue collapse: from KRW 55.4bn (FY2021) to KRW 2.0bn (FY2025), a -56.4% CAGR (Butler.works).
  • Persistent losses: cumulative net losses of about KRW 111.5bn over FY2022–FY2025 (Butler.works).
  • Two consecutive audit disclaimers: FY2024 and FY2025, both citing scope limitation and going-concern doubt (Topstar, Apr 2026).
  • Liquidity: current ratio of 27.3% in FY2025, down from 135.4% in FY2023 (TheVC). Equity fully impaired at 30 June 2026 (KRX).
  • Capability erosion: about 9 employees in June 2026 (TheVC), compared with 78 in a prior Morningstar profile.
  • Missed plans: the Genocare target of at least KRW 20bn revenue (2024) and at least KRW 50bn (2025) was missed by 58% and 96% respectively (Asiae; Butler.works).

Opportunities

  • Injunction outcome: the court may suspend the 8 June 2026 delisting decision (case 2026카합1390, pending). Courts granted other KOSDAQ injunctions in October 2026, though on market-cap-rule grounds.
  • Investor-led rehabilitation re-filing: the company says it will re-file once an investor is secured (Bloter, Aug 2026).
  • Shell value: IB sources noted that a KOSDAQ listing, if preserved, plus real estate could attract buyers (Financial News, Jul 2025).
  • Sector M&A precedent: EDGC was acquired out of rehabilitation by Erom Holdings for KRW 31.5bn (Dealsite, Jan 2026), showing buyer appetite for distressed genomics assets.
  • Asset sales: disposal of the New Oriental Hotel (bought for KRW 18.5bn) could fund creditor settlements (Bizwatch, Nov 2025).
  • Structural demand for early cancer detection: this remains a growth area with continuing capital inflows (Bizwatch, Nov 2025).

Threats

  • Delisting: KRX has already decided. Only a court order prevents execution (CBC News, Jun 2026).
  • Bankruptcy: a bankruptcy petition is pending (Nov 2025). With rehabilitation terminated, creditors can enforce again (Bloter, Aug 2026).
  • Criminal proceedings: complaints against the CEO in Sep 2025 and Aug 2026 allege market manipulation and breach of trust (Chosun Biz; TheVC).
  • Multiple independent delisting triggers: quarterly revenue below KRW 300m, H1 revenue below KRW 700m, full capital impairment and rehabilitation termination (KRX notices, May–Aug 2026). These would survive a favourable injunction on the audit-opinion ground.
  • Creditor enforcement against hard assets: the hotel was pledged as security for a KRW 12bn CB (2024).
  • Industry-wide skepticism toward special-listing biotech and stricter KOSDAQ exit rules (Bizwatch, May 2025; TheVC news 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4 Apr 2025Trading halted; FY2024 disclaimer of opinion creates a delisting cause Nate/Digital TodayStart of the delisting process
7 Apr 2025Fifth-series CB (issued 18 Mar 2025) redeemed early Chosun BizLater cited in breach-of-trust allegations
16 Apr 2025Record date set for capital reduction IRGOProcedural
17 Apr 202593.33% (15:1) capital reduction completed IRGO; BloterDeficit offset; share count about 2.5m
21 Apr 2025Answer to KRX inquiry on unusual price movement: no material information IRGOPrice volatility around the reduction
23 Apr 2025Halt period amended for relisting of post-reduction shares IRGOProcedural
Late May 2025KRX grants an improvement period to April 2026 Bizwatch (May 2025)Delays the delisting decision
16 Jul 2025Samil PwC hired; stalking-horse sale launched Financial NewsAttempt to find a new owner
22 Jul 2025EGM convening resolution (amended) IRGO–
14 Aug 2025H1 2025 report filed IRGOPeriodic
22 Aug 2025CEO's company Brand Refactoring becomes largest shareholder of Dongsung Pharmaceutical AsiaeGovernance concern
8 Sep 2025Rehabilitation application at Suwon Rehabilitation Court The TrackerFormal insolvency process begins
25 Sep 2025CB investor files criminal complaint against the CEO (alleged market manipulation and aggravated breach of trust); reported to FSS and KRX Chosun BizLegal and regulatory risk
30 Sep 2025Rehabilitation commencement decision; halt period amended IRGOCreditor stay
27 Oct 2025Correction to rehabilitation commencement notice IRGOProcedural
3 Nov 2025Bankruptcy petition disclosed; additional halt ground IRGO; TopstarRisk of liquidation
14 Nov 2025Q3 2025 report filed IRGOPeriodic
20 Nov 2025Press reports the company is close to delisting and bankruptcy BizwatchMarket sentiment
9, 15 & 23 Dec 2025Further rehabilitation notice corrections; record date set IRGOProcedural
7 Apr 2026FY2025 disclaimer of opinion; second delisting cause TopstarRemoves the path to resumption
17 Apr 2026FY2024 improvement period ends EdailyKRX review clock starts
28 Apr 2026Objection to delisting filed; KRX to consider both disclaimers together TopstarProcedural defence
15 May 2026Q1 standalone revenue about KRW 24m triggers a substantive-review cause; rehabilitation plan deadline extended from 19 May to 16 Jun 2026 Nate/Bloter; DealsiteMain business considered suspended
8 Jun 2026KRX corporate review committee decides to delist; liquidation trading set for 10–18 Jun, delisting 19 Jun Topstar; CBC NewsTerminal decision
9 Jun 2026Injunction filed (Seoul Southern District Court, 2026카합1390); KRX suspends liquidation trading CBC NewsDelisting stayed
10 Jun 2026Trading suspended for investor protection until the court rules TopstarProcedural
11 Aug 2026Complaint against the CEO lodged with Suwon District Prosecutors' Office (breach of trust, Capital Markets Act); alleges management-linked investments were repaid first TheVC (citing Chosun Biz)Criminal exposure
14 Aug 2026H1 2026 report: Q2 revenue below KRW 300m, H1 below KRW 700m; equity fully impaired; review opinion not unqualified Topstar; Butler.worksFurther substantive-review causes
20/24 Aug 2026Rehabilitation terminated because no plan was filed; disclosed 24 Aug. KRX says this is a further substantive-review cause but will not act while the injunction is pending. Bloter; ChickStockCreditors regain enforcement rights
23 Sep 2026Head-office relocation disclosed Saramin–
Oct 2026 (context)Seoul Southern District Court grants delisting injunctions to other KOSDAQ companies (e.g., Jooyontech, KM Pharm) on market-cap-rule procedural grounds Newspim; BioTimesShows courts do stay KRX decisions, though on different grounds than Celestra's audit-disclaimer case

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total consolidated revenue fell from KRW 11,400 Mn in FY2023 to KRW 2,000 Mn in FY2025.
Clinomics Inc. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total consolidated revenue11,4008,5002,000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bizwatch via Daum, "[Inside Story] Celestra" (20 Nov 2025) (v.daum.net)
  2. Butler.works, Celestra company page (FY2021–FY2025 financials; recent filings) (butler.works)
  3. Butler.works, Macrogen company page (butler.works)
  4. Bullstory, Macrogen financials (OpenDART) (bullstory.io)
  5. CBC News, injunction filing (9 Jun 2026) (cbci.co.kr)
  6. Topstar News, liquidation trading schedule (Jun 2026) (topstarnews.net)
  7. Topstar News, delisting held (9 Jun 2026) (topstarnews.net)
  8. Topstar News, trading suspension (10 Jun 2026) (topstarnews.net)
  9. Topstar News, objection filed (28 Apr 2026) (topstarnews.net)
  10. Topstar News, substantive-review causes added (14 Aug 2026) (topstarnews.net)
  11. Topstar News, substantive-review deadline (18 May 2026) (topstarnews.net)
  12. Topstar News, halt continues (May 2026) (topstarnews.net)
  13. Edaily, improvement period ends (Apr 2026) (edaily.co.kr)
  14. Nate / Digital Today, halt period change (7 Apr 2026) (m.news.nate.com)
  15. Nate / Bloter, Q1 2026 revenue KRW 24.08m (15 May 2026) (m.news.nate.com)
  16. Bloter, rehabilitation terminated (Aug 2026) (bloter.net)
  17. Nate (Bloter syndication), rehabilitation terminated (m.news.nate.com)
  18. ChickStock, KRX market notice (24 Aug 2026) (chickstockfi.com)
  19. Saramin, DART filing list incl. head-office relocation (23 Sep 2026) (saramin.co.kr)
  20. IRGO, Celestra disclosure list (m.irgo.co.kr)
  21. IRGO, Celestra IR page / main products (m.irgo.co.kr)
  22. TheVC, Celestra profile (employees, patents, current ratio, news) (thevc.kr)
  23. Dealsite, rehabilitation plan deadline extended (15 May 2026) (dealsite.co.kr)
  24. Dealsite, diversification and pre-tax-loss ratio (Jul 2024) (dealsite.co.kr)
  25. Dealsite, fifth-series CB (Mar 2025) (dealsite.co.kr)
  26. Dealsite, Nuribio stake (Nov 2022) (dealsite.co.kr)
  27. Dealsite, EDGC acquisition by Erom Holdings (Jan 2026) (dealsite.co.kr)
  28. Dealsite, Celemics performance (Oct 2025) (dealsite.co.kr)
  29. Dealsite, Labgenomics post-COVID (Feb 2023) (dealsite.co.kr)
  30. Chosun Biz via Daum, complaint against CEO (Sep 2025) (v.daum.net)
  31. Financial News, sale adviser and stalking horse (Jul 2025) (fnnews.com)
  32. Nate (Financial News syndication) (news.nate.com)
  33. The Tracker, rehabilitation filing (Sep 2025) (thetracker.co.kr)
  34. Asiae, Brand Refactoring / Dongsung Pharm (Aug 2025) (core.asiae.co.kr)
  35. Asiae, Genocare project (Jul 2024) (core.asiae.co.kr)
  36. Daum/news, rights offering and CBs; hotel financing (2024) (v.daum.net)
  37. KIND, ownership report by Geno Investment Association No. 1 (May 2024) (kind.krx.co.kr)
  38. KIND, Q1 2024 quarterly report correction (kind.krx.co.kr)
  39. NewsTomato, rights offering and CB repayment (Jul 2023) (newstomato.com)
  40. Medigate News, rights offering / Singlera / CoNF (May 2023) (medigatenews.com)
  41. Medigate News, Humic MOU (Aug 2023) (medigatenews.com)
  42. Medigate News, healthcare business / Genpic / Episday (Oct 2022) (medigatenews.com)
  43. Daishin Securities, IPO-manager report (Jun 2021) (file.alphasquare.co.kr)
  44. DailyPharm, pre-IPO funding (May 2019) (dailypharm.com)
  45. DailyPharm, DTC testing and IPO plans (Aug 2018) (m.dailypharm.com)
  46. UNIST News, High-Tech Company designation (May 2022) (news.unist.ac.kr)
  47. Biospectator, founder on CTC/ctDNA platform (biospectator.com)
  48. Bizwatch, special-listing exits (May 2025) (news.bizwatch.co.kr)
  49. EMIS company profile (emis.cn)
  50. GuruFocus summary (test.gurufocus.com)
  51. Morningstar AU quote page (morningstar.com.au)
  52. Simply Wall St, Celestra stock report (simplywall.st)
  53. Simply Wall St, P/S article (simplywall.st)
  54. Investing.com (KR), Celestra quote (kr.investing.com)
  55. Craft.co, Clinomics (craft.co)
  56. CB Insights, Clinomics (cbinsights.com)
  57. MedicalTimes, Macrogen FY2025 (medicaltimes.com)
  58. Newspim, KOSDAQ injunctions granted (Oct 2026) (newspim.com)
  59. BioTimes, delisting deferrals (Oct 2026) (biotimes.co.kr)
  60. Barchart / GlobeNewswire, 23andMe delisting (May 2025) (barchart.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.